ASH News Daily 2013 - Day 2 - (Page A-15)

Advertisement Attention: Investigators/Physicians Idelalisib Clinical Trial Program Recruiting for iNHL and CLL Patients Idelalisib is an investigational product and its safety and efficacy have not been established. Gilead is actively recruiting patients for the WATERFALL clinical program of idelalisib in indolent Non-Hodgkin's Lymphoma (iNHL) and Chronic Lymphocytic Lymphoma (CLL). Formerly known as CAL-101 and GS-1101, idelalisib is an oral investigational product that, based on pre-clinical data, selectively targets phosphatidylinositol 3-kinase (PI3K) delta. It is being developed both as a single agent and in combination with approved and investigational therapies. Of the 10 studies in the WATERFALL program, 4 are currently recruiting patients: * Relapsed/refractory iNHL - Study 124 - Phase 3, randomized, double-blind, placebo-controlled study of idelalisib in combination with rituximab - Study 125 - Phase 3, randomized, double-blind, placebo-controlled study of idelalisib in combination with bendamustine and rituximab * Relapsed/refractory CLL - Study 115 - Phase 3, randomized, double-blind, placebo-controlled study of idelalisib in combination with bendamustine and rituximab - Study 119 - Phase 3, randomized, controlled study of idelalisib in combination with ofatumumab Studies of idelalisib in treatment naive CLL patients are planned but not yet recruiting. - Study 118 - Phase 3, randomized, double-blind, placebo-controlled study of idelalisib in combination with either rituximab or chlorambucil - Study 123 - Phase 3, randomized, double-blind, placebo-controlled study of idelalisib in combination with bendamustine and rituximab For more information, or to refer patients to a WATERFALL study, visit: * Exhibition booth 3428 * www.clinicaltrials.gov The WATERFALL program website can be found at www.WaterfallStudies.com The WATERFALL clinical program reflects Gilead's commitment to addressing the needs of patients with significant unmet medical need. Adverse events will be reported per study requirements. Gilead_Advertorial_Ash_Nov_V6_071113.indd 1 07/11/2013 10:19

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2

Table of Contents

ASH News Daily 2013 - Day 2

https://www.nxtbookmedia.com